Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of MG-K10 in chronic rhinosinusitis with nasal polyps
ChiCTR2600135735Phase 3Not yet recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of comekibart in chronic rhinosinusitis with nasal polyps (CRSwNP) (2 arms), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoints: Change from baseline in Nasal Polyp Score at Week 24 and Change from baseline in Nasal Congestion Score at Week 24. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
comekibart
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on ChiCTR2600135735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135735.